Kurs & Likviditet
Prenumeration
Kalender
2025-02-20 | Bokslutskommuniké 2024 |
2024-11-21 | Kvartalsrapport 2024-Q3 |
2024-08-28 | Kvartalsrapport 2024-Q2 |
2024-05-30 | Kvartalsrapport 2024-Q1 |
2024-05-16 | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2024-05-15 | Årsstämma |
2024-02-27 | Extra Bolagsstämma 2024 |
2024-02-22 | Bokslutskommuniké 2023 |
2023-11-28 | Kvartalsrapport 2023-Q3 |
2023-08-30 | Kvartalsrapport 2023-Q2 |
2023-05-30 | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2023-05-29 | Kvartalsrapport 2023-Q1 |
2023-05-29 | Årsstämma |
2023-03-13 | Bokslutskommuniké 2022 |
2023-01-09 | Extra Bolagsstämma 2022 |
2022-11-28 | Kvartalsrapport 2022-Q3 |
2022-08-25 | Kvartalsrapport 2022-Q2 |
2022-06-02 | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2022-06-01 | Årsstämma |
2022-05-24 | Kvartalsrapport 2022-Q1 |
2022-02-23 | Bokslutskommuniké 2021 |
2021-11-22 | Kvartalsrapport 2021-Q3 |
2021-08-26 | Kvartalsrapport 2021-Q2 |
2021-05-18 | Kvartalsrapport 2021-Q1 |
2021-05-18 | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2021-05-17 | Årsstämma |
2021-02-25 | Bokslutskommuniké 2020 |
2020-11-19 | Kvartalsrapport 2020-Q3 |
2020-08-20 | Kvartalsrapport 2020-Q2 |
2020-05-15 | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2020-05-14 | Kvartalsrapport 2020-Q1 |
2020-05-14 | Årsstämma |
2020-02-27 | Bokslutskommuniké 2019 |
2019-11-28 | Kvartalsrapport 2019-Q3 |
2019-08-29 | Kvartalsrapport 2019-Q2 |
2019-05-17 | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2019-05-16 | Kvartalsrapport 2019-Q1 |
2019-05-16 | Årsstämma |
2019-02-28 | Bokslutskommuniké 2018 |
2018-11-29 | Kvartalsrapport 2018-Q3 |
2018-08-30 | Kvartalsrapport 2018-Q2 |
2018-05-17 | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2018-05-16 | Kvartalsrapport 2018-Q1 |
2018-05-16 | Årsstämma |
2018-02-22 | Bokslutskommuniké 2017 |
2017-11-09 | Kvartalsrapport 2017-Q3 |
2017-10-06 | Extra Bolagsstämma 2017 |
2017-08-31 | Kvartalsrapport 2017-Q2 |
2017-05-12 | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2017-05-11 | Årsstämma |
2017-05-11 | Kvartalsrapport 2017-Q1 |
2017-02-23 | Bokslutskommuniké 2016 |
2016-10-27 | Kvartalsrapport 2016-Q3 |
2016-08-24 | Kvartalsrapport 2016-Q2 |
2016-06-09 | Extra Bolagsstämma 2016 |
2016-04-22 | Årsstämma |
2016-04-22 | Kvartalsrapport 2016-Q1 |
2016-04-21 | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2016-02-10 | Bokslutskommuniké 2015 |
2015-10-29 | Kvartalsrapport 2015-Q3 |
2015-08-13 | Kvartalsrapport 2015-Q2 |
2015-04-22 | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2015-04-21 | Årsstämma |
2015-04-21 | Kvartalsrapport 2015-Q1 |
2015-02-20 | Bokslutskommuniké 2014 |
2014-11-11 | Kvartalsrapport 2014-Q3 |
2014-08-21 | Kvartalsrapport 2014-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
The board of LIDDS AB (publ) has decided to move forward the Annual General Meeting of shareholders 2024 and the publication of the Annual report for 2023. The Annual General Meeting will be held on 27 May 2024 and publication of the Annual report for 2023 will be made on 6 May 2024.
Previous dates for publication of the Annual report for 2023 were 23 April 2024 and the Annual General Meeting 15 May 2024. The move is made primarily to be able to include more information about the acquisition of Noviga Research AB.
For additional information, please contact
Jenni Björnulfson, CEO and CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com
LIDDS’ Certified Adviser is Redeye AB
LIDDS in brief:
LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. LIDDS offers the NanoZolid technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. The company is listed on Nasdaq First North Growth market.